BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, June 20, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2013

View Archived Issues

Trametinib dimethyl sulfoxide plus gemcitabine does not improve outcomes in pancreatic cancer

Read More

Results presented from phase II trial of axitinib in hepatocellular carcinoma

Read More

Bristol-Myers Squibb reviews progress of fourth quarter 2012

Read More

Algeta begins research program on epratuzumab-based targeted thorium conjugate

Read More

Phase III APEX study to be expanded into China

Read More

AiCuris passes enrollment milestone in phase II pritelivir study

Read More

CNRS discloses novel antibodies for cancer and other disorders

Read More

Kalvista Pharmaceuticals synthesizes new plasma kallikrein inhibitors

Read More

New PDE2A/PDE10A inhibitors disclosed by Janssen Pharmaceutical

Read More

Japanese group divulges new mraY inhibitors for bacterial infections

Read More

New antibacterial cephem compounds reported by Shionogi & Co.

Read More

Shionogi & Co. presents novel agents for HIV

Read More

Combination of luminespib and capecitabine well tolerated

Read More

Results from the first of two phase III tavaborole trials reported

Read More

Acceleron begins phase II study of ACE-536 for anemia in MDS

Read More

4-Antibody and the Ludwig Institute expand oncology antibody program

Read More

Prosensa's Duchenne muscular dystrophy products achieve orphan drug status

Read More

IRL-1620 demonstrates neuroprotection in cerebral ischemia model

Read More

OncoPep begins phase I/IIa trial of multipeptide vaccine in smoldering multiple myeloma

Read More

FDA clears IND application for ICT-140

Read More

FDA approves Kynamro for homozygous familial hypercholesterolemia

Read More

FDA advisory committee recommends approval of olodaterol for COPD

Read More

Kissei seeks Japanese approval of dexrazoxane for use in anthracycline extravasation

Read More

OrbeShield granted fast track designation for gastrointestinal ARS

Read More

ElMindA and Purdue Pharma establish research agreement in pain

Read More

Genentech licenses rights to Afraxis compounds

Read More

Biotecnol and Chiome to codevelop antibodies for cancer

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Brain with puzzle piece removed

    Gene replacement rescues autism-related phenotypes in mice

    BioWorld Science
    Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
  • Red blood cells, DNA

    For clonal hematopoiesis, epigenetics can be in driver’s seat

    BioWorld Science
    Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
  • Illustration of amyloid plaques in Alzheimer's disease

    Elixiron’s enrupatinib shows upbeat interim phase II AD results

    BioWorld
    Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing